Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02260986 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Phase 3 study of Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 740
- Enrollment target
- 20
- Study locations
NCT02260986 is a Phase 3 study of Atopic Dermatitis that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 740 participants, above the 605-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT02260986, a Phase 3 study of Atopic Dermatitis, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 740 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD) compared to placebo administered concomitantly with TCS.
Conditions Studied
Interventions
- DRUG Dupilumab
- DRUG Placebo (for Dupilumab)
- OTHER Topical Corticosteroid (TCS)
Study Locations (20)
Florida
- - Edgewater
- - Lake Worth
- - Miami Lakes
- - Orlando
- - Tampa
California
- - Encinitas
- - Oceanside
- - Palmdale
- - San Diego
Georgia
- - Alpharetta
- - Columbus
- - Savannah
Arkansas
- - Hot Springs
- - Little Rock
Connecticut
- - New Haven
- - Trumbull
Indiana
- - Carmel
- - New Albany
Arizona
- - Phoenix
Illinois
- - West Dundee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 740 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02260986
The ClinicalTrials.gov registry entry for NCT02260986 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 740 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 605-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (22% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Dupilumab is the first listed.
NCT02260986 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02260986 about?
NCT02260986 is a clinical study titled "Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis". The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD) compared to placebo administered concomitantly with TCS.
What is the current status of trial NCT02260986?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 740 participants. The study started on 2014-09. Estimated completion is 2016-10.
What conditions does trial NCT02260986 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT02260986?
The interventions under investigation include: Dupilumab (DRUG), Placebo (for Dupilumab) (DRUG), Topical Corticosteroid (TCS) (OTHER).
Who is sponsoring clinical trial NCT02260986?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02260986 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.